Compound kushen injection (CKI) has been used for about 10 years in Chinese clinics as an adjunct to western chemotherapy but how it works has previously not been known.
South Australian Researchers at the University of Adelaide used high-throughput next generation sequencing technologies to identify genes and biological pathways targeted by CKI when applied to breast cancer cells grown in the laboratory.
Study leader Professor David Adelson, Director of the Zhendong Australia – China Centre for the Molecular Basis of Traditional Chinese Medicine, said the technique could be used to analyse the molecular mechanisms of other Traditional Chinese Medicines, potentially opening the way for their use in western medicine.
“This is one of the first studies to show the molecular mode of action of a complex mixture of plant-based compounds – in this case extracts from the roots of two medicinal herbs, Kushen and Baituling – by applying what’s known as a systems biology approach,” he said.
“This is a way of analysing complex biological systems that attempts to take into account all measurable aspects of the system rather than focusing on a single variable.
“We showed that the patterns of gene expression triggered by CKI affect the same pathways as western chemotherapy but by acting on different genes in the same pathways.”
The study, published in the journal Oncotarget, is one of the first to characterise the molecular action of a Traditional Chinese Medicine rather than breaking it down to its constituent parts.
“Most Traditional Chinese Medicines are based on hundreds or thousands of years of experience with their use in China,” Professor Adelson said.
“There is often plenty of evidence that these medicines have a therapeutic benefit, but there isn’t the understanding of how or why.”
Professor Adelson said chemotherapy was once viewed as a “magic bullet” where a single drug was aimed at a single target to kill cancers. However, he said this approach had not proven to be entirely successful and led to resistance in tumours and side effects.
“People are now talking about doing multi-drug treatment of cancer using combinations of known drugs to improve efficacy and reduce side effects,” Professor Adelson said.
“Traditional Chinese Medicine is a combination of many ingredients and our hypothesis is that these multiple compounds in there have some level of activity that have significant effects.
“When you look at the entire cocktail of all of the compounds, can we see effects in cancer cells that support that? The answer is yes we can.”
The Zhendong Australia China Centre for Molecular Traditional Chinese Medicine was established at the University of Adelaide in 2012 in a collaboration with the China-based Shanxi College of Traditional Chinese Medicine and Zhendong Pharmaceutical Company.
The Centre was established with a donation by the Zhendong Pharmaceutical Company, with the aim of understanding how Traditional Chinese Medicine works, and the long-term aim of possible integration into western medicine.
Professor Adelson said the research would likely lead to clinical trials in western countries.
“One of the pre-requisites for clinical trials is to be able to demonstrate some plausible molecular mechanism and that’s one of the things we provide here,” he said.
“This is the first stage of the research so we’re now looking at additional types of cancer cell lines to see what the common pathways might be.
“We are also beginning work to see whether or not the drug modulates the immune system and through that indirect effect also have an affect on cancer cells.”
South Australia’s capital Adelaide has three long-standing public universities, Flinders University, University of South Australia, and the University of Adelaide, each of which are consistently rated highly in the international higher education rankings.Jump to next article